Circular Genomics Raises $15 Million Series A to Advance Circular RNA Diagnostics for Neurological Disorders
Circular Genomics, a biotechnology company pioneering circular RNA (circRNA) biomarker technology for precision diagnostics in neurological and psychiatric conditions, has secured multiple rounds of funding to advance its platform from research to clinical and commercial readiness. The company’s proprietary circRNA assays are designed to improve early detection and treatment personalization for disorders such as Alzheimer’s disease, major depressive disorder, and other brain conditions by offering highly stable, biologically informative biomarkers measured from blood.
The company’s most recent financing came in late 2025, when Circular Genomics announced the successful closing of a $15 million Series A funding round to accelerate clinical validation and the commercialization of its circRNA biomarker platform focused on the early detection of Alzheimer’s disease. The round was led by Mountain Group Partners, a venture capital firm that invests in early‑stage life science and technology companies, with participation from Poplar Grove Investors, HIP Fund, and the Alzheimer’s Drug Discovery Foundation. This latest infusion of capital positions Circular Genomics to expand its clinical programs, grow its team across clinical development, regulatory, and commercial functions, and deepen collaborations with academic institutions and industry partners to bring its diagnostic tests toward broad clinical use.
Circular Genomics’ technology leverages circRNAs — highly stable, brain‑enriched RNA molecules — as biomarkers that reflect disrupted biological pathways central to Alzheimer’s disease and other neurological conditions. By capturing a broad transcriptomic snapshot of disease‑relevant signals from blood, the platform aims to enable earlier and more precise diagnosis than traditional, invasive methods like PET imaging or cerebrospinal fluid testing. The company’s leaders have emphasized that the new funds will be used to expand validation studies across diverse patient populations, enhance the circRNA platform to encompass additional neurological and psychiatric disorders, and establish strategic partnerships that support accelerated market adoption.
Prior to this most recent raise, Circular Genomics completed an earlier Series A financing in 2024 as part of its journey toward launching circRNA‑based clinical assays. That round, amounting to $8.3 million, was also led by Mountain Group Partners and included new investor UNM Rainforest Innovations alongside initial investors such as Cottonwood Technology Fund and Tramway Venture Partners. The 2024 funding enabled the company to build and scale commercial operations in preparation for introducing the world’s first circular RNA‑based clinical assay, with an initial focus on precision psychiatry applications such as predicting patients’ responses to antidepressants.
Circular Genomics’ funding history dates further back to its seed stage, with the company closing an early $4.5 million Series Seed investment that was co‑led by Cottonwood Technology Fund and Tramway Venture Partners alongside Mountain Group Partners. This initial capital supported establishment of laboratory capabilities, early validation cohorts, and the development of circRNA markers intended to guide personalized treatment decisions for psychiatric and neurological disorders.
With these successive rounds, Circular Genomics has raised a total of more than $30 million in disclosed funding through various equity financings. The company’s investor base spans traditional venture capital firms, specialized life sciences funds, university innovation programs, and non‑profit foundations supporting disease research. This breadth reflects both the scientific promise of circular RNA biomarkers and the urgency of developing accessible, minimally invasive diagnostics for conditions with high unmet medical need.
Circular Genomics’ leadership has consistently emphasized the transformative potential of its circRNA platform to shift disease detection and management paradigms. By providing a biologically grounded view of complex brain disorders from a simple blood draw, the company aims to facilitate earlier intervention, more precise patient stratification, and ultimately better clinical outcomes. The latest Series A funding, led by Mountain Group Partners and joined by investors with deep expertise in healthcare and diagnostics, underscores confidence in the company’s path from cutting‑edge research to real‑world impact.
In addition to expanding its clinical validation efforts, Circular Genomics is actively pursuing strategic collaborations with academic institutions, pharmaceutical developers, and diagnostic service providers. The company’s long‑term vision encompasses a suite of circRNA‑based tests spanning Alzheimer’s disease, depression, bipolar disorder, and other neurological conditions, with the goal of enhancing diagnostic accuracy and enabling personalized therapeutic decision‑making at scale.
With its expanded financial runway and strategic investor support, Circular Genomics is advancing the development of next‑generation molecular diagnostics that could redefine how clinicians detect and manage brain disorders, offering new hope for patients and families affected by some of the most challenging diseases in neurology and psychiatry.
